The U.S. Food and Drug Administration announced on 8/22/18 that it has approved the first drug, Oxervate (cenegermin), for the treatment of neurotrophic keratitis, a rare disease affecting the cornea (the clear layer that covers the colored portion of the front of the eye). Qxervate was developed by the Italian pharmaceutical company Dompé farmaceutici SpA.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,